Pan European Collaboration on Antipsychotic Naïve Schizophrenia II

Trial Profile

Pan European Collaboration on Antipsychotic Naïve Schizophrenia II

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 25 May 2016

At a glance

  • Drugs Aripiprazole (Primary)
  • Indications Schizophrenia
  • Focus Pharmacodynamics
  • Acronyms PECANS II
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 12 May 2016 Planned number of patients changed from 120 to 200.
    • 12 May 2016 Planned End Date changed from 1 Dec 2019 to 1 Dec 2020.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top